Holen Sie sich die Stockscreener-App
57.33
1.83%
1.03
Handel nachbörslich:
57.54
0.21
+0.37%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$56.30
Offen:
$56.22
24-Stunden-Volumen:
40.36M
Relative Volume:
3.63
Marktkapitalisierung:
$116.28B
Einnahmen:
$47.44B
Nettoeinkommen (Verlust:
$-7.26B
KGV:
14.55
EPS:
3.94
Netto-Cashflow:
$13.80B
1W Leistung:
+2.78%
1M Leistung:
-0.95%
6M Leistung:
+39.69%
1J Leistung:
+12.50%
1-Tages-Spanne:
$56.08
$57.33
1-Wochen-Bereich:
$55.68
$58.55
52-Wochen-Spanne:
$39.35
$61.08
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Vergleichen Sie BMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
57.33 | 116.28B | 47.44B | -7.26B | 13.80B | -3.59 |
|
LLY
Lilly Eli Co
|
767.76 | 690.46B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
85.00 | 377.54B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
144.47 | 347.83B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
175.58 | 310.27B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
98.05 | 248.03B | 63.17B | 12.15B | 14.84B | 4.77 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Principal Financial Group Inc. - MarketBeat
M&T Bank Corp Reduces Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Squibb licenses Bioarctic’s Aβ antibody program - BioWorld Online
Bristol-Myers Squibb Stock Will Handle Patent Cliff And Is Still Undervalued (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb licenses amyloid-beta antibody programme - European Pharmaceutical Review
Bristol Myers wins US FDA approval for new type of schizophrenia drug - AOL
Jim Cramer on Bristol-Myers Squibb Company (BMY): ‘This Stock Has Been Hot Since The Summer’ - Yahoo Finance
Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today - Yahoo Finance
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors - MarketWatch
Bristol Myers Squibb Stock Earns 83 RS Rating - Yahoo! Voices
Jim Cramer on Bristol-Myers Squibb (BMY): Why Schizophrenia Drug Cobenfy Could Change the Game - Yahoo Finance UK
Fangzhou partners with Bristol Myers Squibb in China - The Pharma Letter
One Community at a Time: Enabling Early Lung Cancer Detection Across the U.S. - CSRwire.com
Bristol Myers Squibb selects novel ALS target under Insitro collaboration - BioWorld Online
3 High-Yielding Dividend Stocks That Retirees Can Rely On for Recurring Income - The Motley Fool
Imbed Biosciences Appoints Bristol Myers Squibb Veteran Terry Bromley as Chief Executive Officer - The Bakersfield Californian
Bristol Myers enters $100M PyroGlu-Ass license agreement with BioArctic - TipRanks
Leqembi creator to work with Bristol Myers in $1.3 billion deal - The Pharma Letter
Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025 - The Bakersfield Californian
JPMorgan optimistic on Bristol-Myers Squibb shares as valuation discounts peer comparisons - Investing.com
Fangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare - BioSpace
BioArctic Inks Massive $1.35B Alzheimer's Drug Deal with Bristol Myers Squibb - StockTitan
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Here is the full article based on the provided information: - Investing.com
Is Bristol-Myers Squibb Company (BMY) the Best Cash-Rich Dividend Stock to Invest In Now? - Yahoo Finance
Bristol Myers Squibb Foundation Launches Major Lung Cancer Screening Initiative with $9.3M Investment - StockTitan
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Bristol Myers Squibb Awards $25M Milestone Payment for Breakthrough ALS Treatment Target Discovery - StockTitan
Urothelial Cancer Drugs Markets and Competitive Landscape - GlobeNewswire
Is Bristol-Myers Squibb Company (BMY) the Best Weight Loss Stock to Buy Now According to Hedge Funds? - Yahoo Finance
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga
Bristol Myers upgraded to Buy at Jefferies on new launch momentum, pipeline - Yahoo Finance
ASH: Out With The Old, In With The New As BMS Ushers In CELMoD Class - Citeline News & Insights
Bristol-Myers Climbs After Jefferies Upgrades Stock On Schizophrenia Drug’s $10B Potential: Retail Is Excited - MSN
Bristol Myers Squibb Co. stock rises Monday, still underperforms market - MarketWatch
Jefferies Upgrades Bristol Myers Squibb to ‘buy’ on drug Cobenfy - Investing.com
BMS’ Cost-Cutting Campaign Claims Collabs With Immatics, Century - BioSpace
Bristol-Myers Squibb (NYSE:BMY) Rating Increased to Buy at Jefferies Financial Group - MarketBeat
Bristol Myers drops cell therapy pacts with Immatics, Century as part of portfolio review - Endpoints News
Wellington Management Group LLP Sells 16,518 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Car T Cell Therapy Market Overall Study Report 2024-2031 | - openPR
Century Therapeutics ends collaboration with Bristol-Myers Squibb - Investing.com India
Bristol-Myers Squibb (NYSE:BMY) Will Pay A Larger Dividend Than Last Year At $0.62 - Yahoo Finance
Exome Asset Management LLC Makes New $4.04 Million Investment in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Squibb (BMY) Stock Moves -0.89%: What You Should Know - Yahoo Finance
Padlock investors sue Bristol Myers; Dietmar Berger is Gilead’s new CMO - BioPharma Dive
Global Breakthrough Therapy Designation Market Set to Double by 2029 with Notable CAGR of 13.80% - GlobeNewswire
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Retirement Systems of Alabama - MarketBeat
Inspire Trust Co. N.A. Buys 29,044 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Peapack Gladstone Financial Corp Sells 70,311 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.44%
1.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):